InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants

Rhea-AI Filing Summary

InflaRx N.V. director and Chief Scientific Officer Guo Renfeng filed an initial Form 3 showing his ownership in the company. He directly holds 1,762,144 Ordinary Shares and a series of stock options over additional Ordinary Shares with exercise prices ranging from 1.1700 to 2.4400, expiring between 2027 and 2036. Footnotes state that multiple option grants from 2016 through 2025 are already fully vested and exercisable, while a January 6, 2026 grant vests in four equal quarterly installments and a separate performance option depends on a financing event and the average Ordinary Share price in quarter four of 2026 exceeding $1.50.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Guo Renfeng

(Last) (First) (Middle)

C/O INFLARX N.V.

WINZERLAER STREET 2

(Street)

JENA 07745

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
InflaRx N.V. [ IFRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,762,144	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/18/2031	Ordinary Shares	336,672	$1.86	D
Stock Option (Right to Buy)	(2)	12/13/2027	Ordinary Shares	623,610	$1.86	D
Stock Option (Right to Buy)	(3)	11/20/2028	Ordinary Shares	5,409	$1.86	D
Stock Option (Right to Buy)	(4)	01/04/2031	Ordinary Shares	275,000	$1.86	D
Stock Option (Right to Buy)	(5)	07/01/2031	Ordinary Shares	88,006	$1.86	D
Stock Option (Right to Buy)	(6)	01/11/2032	Ordinary Shares	430,500	$1.86	D
Stock Option (Right to Buy)	(7)	11/21/2032	Ordinary Shares	55,000	$2.44	D
Stock Option (Right to Buy)	(8)	01/24/2033	Ordinary Shares	430,500	$2.37	D
Stock Option (Right to Buy)	(9)	01/05/2034	Ordinary Shares	500,000	$1.79	D
Stock Option (Right to Buy)	(10)	01/03/2035	Ordinary Shares	500,000	$2.41	D
Stock Option (Right to Buy)	(11)	01/06/2036	Ordinary Shares	571,500	$1.17	D
Performance Stock Option (Right to Buy)	(12)	01/06/2036	Ordinary Shares	171,450	$1.17	D

Explanation of Responses:

1. This option was granted on November 18, 2016 and is fully vested and exercisable as of the date hereof.

2. This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof.

3. This option was granted on November 20, 2018 and is fully vested and exercisable as of the date hereof.

4. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.

5. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

6. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

7. This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof.

8. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

9. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

10. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

11. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 142,875 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

12. This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.

Remarks:

Exhibit List - Exhibit 24.1 Power of Attorney

	/s/ Christian Schmid, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Guo Renfeng report owning in InflaRx (IFRX) on this Form 3?

He reports direct ownership of 1,762,144 Ordinary Shares of InflaRx N.V. In addition, he holds multiple stock option grants over further Ordinary Shares with various exercise prices and expiration dates extending out to 2036.

What stock option grants does the InflaRx (IFRX) CSO hold?

He holds several Stock Option (Right to Buy) awards over Ordinary Shares, with exercise prices such as 1.8600, 2.4400, 2.3700, 1.7900, 2.4100 and 1.1700, each with distinct expiration dates from 2027 to 2036.

Which InflaRx (IFRX) options held by Guo Renfeng are already vested?

Footnotes explain that options granted on November 18, 2016, December 13, 2017, November 20, 2018, January 4, 2021, July 2, 2021, January 12, 2022, November 21, 2022, January 24, 2023, January 5, 2024 and January 3, 2025 are fully vested and exercisable.

How does the January 6, 2026 InflaRx (IFRX) option for Guo Renfeng vest?

The option granted on January 6, 2026 for 571,500 underlying Ordinary Shares will vest and become exercisable in four equal installments of 142,875 shares on each quarterly anniversary of that grant date, subject to continued service.

What are the performance conditions on the InflaRx (IFRX) performance stock option?

The performance stock option for 171,450 underlying Ordinary Shares vests in two halves: 50% if a specified financing event occurs before the fourth quarter of 2026, and 50% if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.